
|Articles|October 24, 2012
VMA treatment approved
The FDA has approved ocriplasmin (Jetrea, ThromboGenics) for the treatment of symptomatic vitreomacular adhesion (VMA).
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Starting from scratch on neovascular age-related macular degeneration
2
AAO 2025: Early optogenetic therapy shows promise for patients with inherited retinal diseases
3
The mechanics of presbyopia: From muscle movement to functional vision
4
Subretinal drusenoid deposits in Black and Hispanic patients with AMD
5